BerGenBio
Sustainability Report and Carbon Intensity Rankings
Is BerGenBio doing their part?
Their DitchCarbon score is 47
BerGenBio has a DitchCarbon Score of 47 out of 100, indicating a moderate level of sustainability in their operations. This score reflects the company’s carbon intensity, which suggests there is significant room for improvement in reducing emissions. A higher score would demonstrate a stronger commitment to lowering carbon intensity and enhancing sustainability efforts.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
BerGenBio is a company in the research and development sector, which has a very low carbon intensity ranking compared to other industries. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.
Location emissions intensity
Very low
Low
Medium
High
Very high
BerGenBio, located in Norway, benefits from the country’s very low carbon intensity, indicating a greener operational environment. This suggests that the company’s sustainability efforts are supported by Norway’s commitment to low carbon emissions.
Unlock 30+ emissions data points on BerGenBio
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on BerGenBio
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
4.36%
...this company is doing 4.36% worse in emissions than the industry average.
BerGenBio, founded in 2008 and based in Bergen, operates within the research and development sector of the biopharmaceutical industry. The company specializes in the development of selective AXL kinase inhibitors, aiming to combat aggressive cancers by targeting mechanisms responsible for cancer spread and drug resistance. As a leader in understanding AXL kinase’s role in cancer, BerGenBio seeks to provide new therapeutic options for patients facing this disease.
emission intelligence's platform recommendations for BerGenBio
BerGenBio should foster the adoption of remote collaboration tools such as video conferencing to minimize business travel, thereby potentially reducing their scope 3 emissions by 0.5%.
Bad news, BerGenBio hasn't committed to SBTi goals yet
BerGenBio has not yet established specific commitments with the Science Based Targets initiative (SBTi). This means the company has not defined or announced clear goals to reduce greenhouse gas emissions in line with climate science.
Not participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.